Humira Biosimilar Switch-Back Rate Hits 16% in US Study
Event summary
- 17.7% of Humira patients switched to biosimilars post-formulary changes in the US.
- 16.0% of those who switched later returned to originator adalimumab (Humira).
- Older adults, women, and ankylosing spondylitis patients were more likely to switch back.
- Rural patients switched back more quickly after initiating biosimilars.
The big picture
The study highlights the complexities of biosimilar adoption in the US, where cost savings are balanced against patient preferences and clinical realities. With adalimumab being one of the most widely used biologics for autoimmune diseases, the findings could influence future formulary decisions and biosimilar strategies across the healthcare system.
What we're watching
- Patient Adherence
- How the switch-back rate will impact long-term biosimilar adoption and patient trust.
- Cost Savings
- Whether health plans can sustain cost savings amid higher-than-expected switch-backs.
- Regulatory Impact
- The pace at which regulators may intervene to address switching patterns and patient outcomes.
Related topics